Stock Analiz

Humacyte, Inc. HUMA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$0.56Market cap $155M
Open the interactive analysis →

Humacyte, Inc. (HUMA) is a healthcare company listed in the US with a market value of about $155M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$95M, a net margin of -3955.1%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -264%.

About Humacyte

Humacyte is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 6 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 3400% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S64.7
P/B8.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-57.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2003.6%
ROIC (5-yr avg.)-263.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$2M$2M$0————
Net income-$95M-$41M-$149M-$111M-$12M-$26M-$67M
Free cash flow-$89M-$106M-$100M-$76M-$72M-$81M-$56M
EPS (diluted)$-0.34$-0.26$-1.26$-1.07$-0.12$-0.66$-11.54
Net margin-3955.1%-2003.6%—————
ROIC—-280.5%-800.8%-149.8%-45.3%-42.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Humacyte pay a dividend?

Not currently.

Is Humacyte a good stock to buy?

We do not give buy or sell advice. Humacyte scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.